PureTech Health (LON:PRTC) Shares Cross Below Fifty Day Moving Average - Here's What Happened

Key Points

• PureTech Health (LON:PRTC) shares fell below their fifty-day moving average
• The stock trades below its 200‑day MA (GBX 126.38) and shows valuation and balance-sheet metrics of a £295.79 million market cap, a P/E of 7.15, a high current ratio of 8.49, quick ratio 2.51 and a debt‑to‑equity ratio of 5.56 (beta 0.71).
• PureTech is a clinical‑stage biopharma developing a microbiome‑immune discovery platform, oral weight‑loss/glycaemic control candidates, and diagnostic/therapeutic technologies for neurological and psychiatric disorders.

PureTech Health plc (LON:PRTC - ) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 121.89 and traded as low as GBX 119.20. PureTech Health shares last traded at GBX 121.52, with a volume of 697,931 shares changing hands.

PureTech Health Price Performance

The stock has a fifty day simple moving average of GBX 121.89 and a 200-day simple moving average of GBX 126.38. The company has a current ratio of 8.49, a quick ratio of 2.51 and a debt-to-equity ratio of 5.56. The stock has a market cap of £295.79 million, a price-to-earnings ratio of 7.15 and a beta of 0.71.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.